Analyst
J.P. Morgan
Equibles does not estimate personal net worth.
Hardik Parikh is recorded as Analyst at J.P. Morgan. Hardik Parikh has spoken on 5 earnings calls across 3 companies, most recently for Viking Therapeutics, Inc. on July 29, 2026. Those appearances were for Pacira BioSciences, Inc. (PCRX), Viking Therapeutics, Inc. (VKTX) and Royalty Pharma plc (RPRX). The companies whose calls Hardik Parikh spoke on are classified in the Healthcare sector.
“And the first one is just on the Phase 3 Oral that Setsa initiate in 4Q. I understand some of the details you can't share with us, but just internally, what are some of the crowd design protocols that you're kind of still working through that's kind of still undecided?”
“I just wanted to ask you about, Sean, I think I heard you say you expect SGMA to be lower in the second half. Can you talk to the magnitude of the step-down? you're expecting to be going to happen, and just, you know, SG&A seems to have elevated the past five quarters relative to 2024.”
“I was just wondering, I know in 4Q you guys said you had some unexpected business development costs. As you guys try to grow and diversify the business, can we think of that as maybe happening more often and kind of having some of these kind of one-off business development types of deals?”
“I'm just wondering, you know, I know Merck had recently announced a royalty deal with one of your peers, and you guys have also done a couple of R&D collaborations with Biogen and Merck in the past.”
“First is just wondering, you mentioned that survey you guys had done, and you're talking about organizations who plan to add Xperl to the formularies. They could take 6 to 12 months to start adopting.”
J.P. Morgan
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
RPRX
Biotechnology · Healthcare
